Literature DB >> 28149601

Continuous infusion of beta-lactams: a blissful option for the intensive care unit.

Andrew F Shorr1, Marya D Zilberberg2.   

Abstract

Entities:  

Year:  2016        PMID： 28149601      PMCID： PMC5227275          DOI： 10.21037/jtd.2016.12.47

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

1.  Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay.

Authors:  Andrew F Shorr; Scott T Micek; Emily C Welch; Joshua A Doherty; Richard M Reichley; Marin H Kollef
Journal:  Crit Care Med       Date:  2011-01       Impact factor: 7.598

2.  Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.

Authors:  Mohd H Abdul-Aziz; Helmi Sulaiman; Mohd-Basri Mat-Nor; Vineya Rai; Kang K Wong; Mohd S Hasan; Azrin N Abd Rahman; Janattul A Jamal; Steven C Wallis; Jeffrey Lipman; Christine E Staatz; Jason A Roberts
Journal:  Intensive Care Med       Date:  2016-01-11       Impact factor: 17.440

3.  Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study.

Authors:  Marya D Zilberberg; Marin H Kollef; Andrew F Shorr
Journal:  J Hosp Med       Date:  2015-09-09       Impact factor: 2.960

4.  Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013).

Authors:  Helio S Sader; Mariana Castanheira; Robert K Flamm; Rodrigo E Mendes; David J Farrell; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2015-06-23       Impact factor: 2.803

5.  National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011.

Authors:  Raymund Dantes; Yi Mu; Ruth Belflower; Deborah Aragon; Ghinwa Dumyati; Lee H Harrison; Fernanda C Lessa; Ruth Lynfield; Joelle Nadle; Susan Petit; Susan M Ray; William Schaffner; John Townes; Scott Fridkin
Journal:  JAMA Intern Med       Date:  2013-11-25       Impact factor: 21.873

6.  Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock.

Authors:  Cristina Vazquez-Guillamet; Michael Scolari; Marya D Zilberberg; Andrew F Shorr; Scott T Micek; Marin Kollef
Journal:  Crit Care Med       Date:  2014-11       Impact factor: 7.598

7.  An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.

Authors:  Scott T Micek; Richard G Wunderink; Marin H Kollef; Catherine Chen; Jordi Rello; Jean Chastre; Massimo Antonelli; Tobias Welte; Bernard Clair; Helmut Ostermann; Esther Calbo; Antoni Torres; Francesco Menichetti; Garrett E Schramm; Vandana Menon
Journal:  Crit Care       Date:  2015-05-06       Impact factor: 9.097

8.  Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study.

Authors:  Marya D Zilberberg; Andrew F Shorr; Scott T Micek; Cristina Vazquez-Guillamet; Marin H Kollef
Journal:  Crit Care       Date:  2014-11-21       Impact factor: 9.097

9.  Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr
Journal:  Crit Care       Date:  2016-07-11       Impact factor: 9.097

10.  Impact of prior probabilities of MRSA as an infectious agent on the accuracy of the emerging molecular diagnostic tests: a model simulation.

Authors:  Marya D Zilberberg; Andrew F Shorr
Journal:  BMJ Open       Date:  2012-12-18       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.